on the Mexico-US border. She was chief of the Division of Global Public Health in UC San Diego's Department of Medicine until 2017. Role in promoting phage therapy In 2016, Strathdee enlisted the help of an international team of physicians and researchers to save her husband's life with bacteriophage (phage) therapy after he acquired a life-threatening infection with a 'superbug', Acinetobacter baumannii. Although phage therapy had been used for one hundred years in Eastern Europe, it was not licensed for clinical use in the United States or most of Western Europe. Her husband, Tom Patterson, appears to be the first person in the U.S. to be successfully cured from a systemic multi-drug-resistant bacterial infection with cocktails of intravenous bacteriophages. After the case was published, it received considerable attention in top medical journals including JAMA and Lancet, as well as numerous reports in the international press, including a TEDx talk and a presentation at the LIFE ITSELF conference. The Guardian listed this case as one of the top science stories of 2017. Since her husband's release from hospital in 2016, Strathdee and her physician friend, Robert "Chip" Schooley, who was responsible for treating her husband, have been actively involved in helping other patients receive phage therapy and have launched the Center for Innovative Phage Applications and Therapeutics (IPATH), the first phage therapy center in North America at UCSD which is assisting patients with life-threatening superbug infections obtain treatment. IPATH's goal is to conduct translational research and rigorous clinical trials to determine if phage therapy is efficacious to enable its licensure and widespread use. Patterson made a full recovery and returned to work in April 2017. Strathdee and her husband have written a book about their story called The Perfect Predator: A Scientists's Race to Save Her Husband from a Deadly Superbug, which was published by Hachette Book Group in 2019. As a result of the Patterson case, dozens other patients with multidrug resistant bacterial infections have been treated with intravenous phage therapy with the help of IPATH, including Joel Grimwood and Isabelle Carnell-Holdaway. Joel Grimwood was a patient who was ineligible for heart transplantation due to antimicrobial resistant infection. With phage and antibiotic infusions, Grimwood was able to become healthy enough to undergo a successful heart transplantation. Isabelle Carnell-Holdaway was a 15-year-old patient that underwent experimental treatment in which she was the first person in the world to be administered genetically